Inhibrx, Inc.

Equities

INBX

US45720L1070

Biotechnology & Medical Research

Market Closed - Nasdaq 04:00:00 2024-02-23 pm EST 5-day change 1st Jan Change
38.28 USD -0.13% Intraday chart for Inhibrx, Inc. +1.59% +0.74%
This article is reserved for members
To unlock the article, REGISTER!
Already a customer? Log In
Arecor Therapeutics hails Arestat as 2023 performance "strong" AN
North American Morning Briefing : S&P 500 Futures Point to Fresh Record on Netflix Results DJ
Health Care Flat After J&J Earnings -- Health Care Roundup DJ
Arecor pleased as investee Inhibrx sells therapy to Sanofi AN
Sector Update: Health Care Stocks Decline Late Afternoon MT
Sector Update: Health Care MT
Sanofi Agrees to Buy Inhibrx' Rare Disease Candidate For Up To $2.2 Billion MT
CAC40: slight decline in the absence of catalysts CF
CAC40: down in the wake of Bunds and US T-Bonds CF
News Highlights : Top Company News of the Day - Tuesday at 11 AM ET DJ
CAC40: falls back below 7,400, Wall-Street reopens unchanged CF
News Highlights : Top Company News of the Day - Tuesday at 9 AM ET DJ
Sector Update: Health Care Stocks Mixed Premarket Tuesday MT
Exchange-Traded Funds Higher, Equity Futures Mixed Pre-Bell Tuesday as Investors Await Earnings Peak MT
Sector Update: Health Care MT
JMP Securities Downgrades Inhibrx to Market Perform From Market Outperform MT
Sanofi to Buy Assets From Inhibrx in Deal Valued at Up to $2.2 Billion -- Update DJ
Sanofi to Acquire Inhibrx for Up to $2.2 Billion MT
European Midday Briefing : Caution Dominates as Focus Back on Big-Name U.S. Earnngs DJ
News Highlights : Top Company News of the Day - Tuesday at 5 AM ET DJ
CAC40: little movement, caution prevails CF
News Highlights : Top Company News of the Day - Tuesday at 3 AM ET DJ
Sanofi: agreement to acquire Inhibrx CF
Sanofi to Buy US-based Biopharmaceutical Group Inhibrx for $1.7 Billion MT
France's Sanofi to buy U.S. drugs project INBRX-101 for around $2.2 bln RE
Chart Inhibrx, Inc.
More charts
Inhibrx, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on developing a pipeline of biologic therapeutic candidates in oncology and orphan diseases. Its clinical pipeline includes therapeutic candidates, such as INBRX-101, INBRX-109, INBRX-105 and INBRX-106. INBRX-101 is an engineered recombinant human alpha-1 antitrypsin fragment crystallizable (AAT-Fc) fusion protein therapeutic candidate that the Company is developing for the treatment of patients with Alpha-1 Antitrypsin Deficiency (AATD) and acute Graft-versus -host-disease (aGvHD). INBRX-109 is an engineered tetravalent therapeutic candidate targeting death-receptor 5 (DR5), a TNFRSF member, also known as tumor necrosis factor-related apoptosis-inducing ligand or TRAIL receptor 2. INBRX-105 is a conditional tetravelent PD-L1 targeted 4-1BB agonist that is being investigated as a single agent and in combination with Keytruda in patients with locally advanced or metastatic solid tumors.
Related indices
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
C
More Ratings
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
3
Last Close Price
38.28 USD
Average target price
35.5 USD
Spread / Average Target
-7.26%
Consensus
1st Jan change Capi.
+0.74% 1 814 M $
+5.69% 111 B $
+11.72% 105 B $
+9.93% 24 182 M $
-10.96% 22 338 M $
-26.36% 21 352 M $
-6.59% 19 088 M $
-14.01% 16 173 M $
+1.84% 13 352 M $
+41.59% 12 772 M $
Bio Therapeutic Drugs
  1. Stock
  2. Equities
  3. Stock Inhibrx, Inc. - Nasdaq
  4. News Inhibrx, Inc.
  5. Arecor Therapeutics to Receive Milestone Payment from Inhibrx
-40% Limited-time offer: Our subscriptions help you unlock the best investment opportunities.
SIGN UP NOW